Drugs Made In America Acquisition Corp. (DMAAR) Net Income (2025 - 2026)
Drugs Made In America Acquisition's (DMAAR) quarterly Net Income came in at $1.7 million in Q2 2026, down 24.54% on a YoY basis from $2.3 million in Q2 2025, and up 710.91% quarter-over-quarter from $212958.0 in Q4 2025.
Analysis
Drugs Made In America Acquisition Corp. (DMAAR) Net Income (2025 - 2026) Analysis & Trends
Drugs Made In America Acquisition (DMAAR) has reported Net Income for 2 consecutive years, with $1.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Income fell 24.54% year-over-year to $1.7 million; the trailing twelve-month figure through Jun 2026 stood at $6.4 million (changed N/A YoY), and the FY2025 full-year result was $5.9 million, up 2222.83% from the prior year.
- Net Income grew to $1.7 million in Q2 2026 per DMAAR's latest filing, from $212958.0 in the prior quarter.
- Across five years, Net Income topped out at $2.3 million in Q2 2025 and bottomed at $212958.0 in Q4 2025.
Peer Set
Peer Comparison
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.73 Mn |
| Dec 31, 2025 | 212,958.00 |
| Sep 30, 2025 | 2.18 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Mar 31, 2025 | 1.25 Mn |